Monocacy Therapeutics files Form D for $25,000 SAFE offering
The Delaware biotech, based in Monrovia, Maryland, reported selling $25,000 in securities to a single investor under a Regulation D exemption.
Monocacy Therapeutics Inc. filed a Form D with the Securities and Exchange Commission disclosing a securities offering. The issuer is a corporation named Monocacy Therapeutics Inc., incorporated in Delaware in 2025.1 Its principal place of business is listed at 4716 Monrovia Blvd, Monrovia, Maryland.1
The filing names two related persons. Suman Vodnala is listed as an Executive Officer, and Shashank Patel is listed as both an Executive Officer and Director.1 Patel signed the filing as President.
The company classified its industry as Biotechnology within the Health Care group.1 It selected "Decline to Disclose" for its revenue or aggregate net asset value range.1
The offering claims an exemption under Rule 506(b).1 The filing is a New Notice with a date of first sale of 2026-09-25.1 The issuer indicated it intends the offering to last more than one year.1
The type of security offered is described as "Other," specifically a Simple Agreement for Future Equity (SAFE).1 The offering is not being made in connection with a business combination transaction.1 The minimum investment accepted from any outside investor is listed as $0.1
The total offering amount and total amount sold are both listed as $25,000, with $0 remaining to be sold.1 The filing states that one investor has already invested in the offering.1 No sales commissions or finders' fees were reported.1 No proceeds were allocated as payments to executive officers, directors, or promoters.1
The notice was signed by Shashank Patel, President, on 2026-10-02.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.